Community hematologist/oncologist perspectives on minimal residual disease testing in patients with multiple myeloma
There are opportunities to reduce the barriers for the use of MRD testing and for generation of additional data on the clinical impact of these test results to support the development of guidelines and provide further education on the implementation of MRD test results in clinical practice and aid clinical decision-making.
Authors
- Trevor Heritage (ORCID: https://orcid.org/0009-0007-8516-925X)
- Lucio Gordan (ORCID: https://orcid.org/0000-0002-3956-1396)
- Annelore Cortoos
- Amanda N. Warner (ORCID: https://orcid.org/0000-0002-4616-089X)
- Niodita Gupta‐Werner
- Shuchita Kaila
- Amy Ming
Institutions
- Johnson & Johnson (United States) (US)
- Florida Cancer Specialists & Research Institute (US)
- Johnson & Johnson (Israel) (IL)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-08-20
- DOI
- https://doi.org/10.1080/14796694.2025.2546284
- Citations
- 2
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.54
Funders
- Johnson and Johnson